Suchergebnisse - "Chowdhury, Paramit"

PubPharm (49)

1

Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome

enthalten in: Transplantation | 2023

von Glover, E. | Smith-Jackson, K. | Brocklebank, V. | +60

2

Incidence, Risk Factors, and Effect on Allograft Survival of Glomerulonephritis Post-transplantation in a United Kingdom Population : Cohort Study

enthalten in: Frontiers in nephrology | 2022

von Aguiar, R. | Bourmpaki, E. | Bunce, C. | +26

3

Outcomes of pregnancy in simultaneous pancreas and kidney transplant recipients : A single-center retrospective study

enthalten in: Clinical transplantation | 2021

von Punjala, S. | Phillips, B. | Chowdhury, P. | +8

4

IgG SARS-CoV-2 Antibodies Persist at Least for 10 Months in Patients on Hemodialysis

enthalten in: Kidney international reports | 2021

von Dudreuilh, C. | Roper, T. | Breen, C. | +4

CommentIn: Kidney Int Rep. 2021 Jul;6(7):1761-1763. - PMID 34124415

5

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

enthalten in: Kidney international reports | 2021

von Barbour, T. | Scully, M. | Ariceta, G. | +54

6

Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296

enthalten in: Kidney international | 2021

von Rondeau, E. | Scully, M. | Ariceta, G. | +61

ErratumFor: Kidney Int. 2020 Jun;97(6):1287-1296. - PMID 32299680

7

Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296

enthalten in: Kidney international | 2020

von Rondeau, E. | Scully, M. | Ariceta, G. | +59

ErratumFor: Kidney Int. 2020 Jun;97(6):1287-1296. - PMID 32299680

8

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

enthalten in: Kidney international | 2020

von Rondeau, E. | Scully, M. | Ariceta, G. | +59

ErratumIn: Kidney Int. 2020 Dec;98(6):1621. - PMID 33276869

9

Incorporating apolipoprotein L1 testing into evaluation of potential living kidney donors : a single-centre experience

enthalten in: Clinical kidney journal | 2019

von Dick, J. | Asgari, E. | Chowdhury, P. | +7

10

Gene expression biomarkers for kidney transplant rejection-The entire landscape-Author's reply

enthalten in: EBioMedicine | 2019

von Christakoudi, S. | Runglall, M. | Chowdhury, P. | +1

1
2
3
4
5
Nächster »
[5]